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Introduction. Certain clinicopathological factors are associated with a higher likelihood of distant metastases in primary breast
cancer. However, there remains inconsistency in which patients undergo formal staging for distant metastasis and the most
appropriate investigation(s). Aims. To identify UK surgeon preferences and practice with regard to staging investigations for
distant metastases. Methods. A survey was disseminated to members of the Association of Breast Surgery by e-mail regarding
surgeon/breast unit demographics, use of staging investigations, and local policy on pre/postoperative staging investigations.
Several patient scenarios were also presented. Results. 123 of 474 (25.9%) recipients completed the survey. Investigations routinely
employed for patients diagnosed with early breast cancer included serological/haematological tests (72% respondents), axillary
ultrasound (67%), liver ultrasound (2%), chest radiograph (36%), and computed tomography (CT) (1%). Three areas contributed
to decisions to undertake staging by CT scan: tumour size, axillary nodal status, and plan for chemotherapy.There was widespread
variation as to criteria for CT staging based on tumour size and nodal status, as well as the choice of staging investigation for the
clinical scenarios presented. Conclusions. There remains variation in the use of staging investigations for distant disease in early
breastcancer despite available guidelines.
1. Introduction
Accurate disease staging is important in decision-making for
patients with primary breast cancer, both in treatment plan-
ning (locoregional versus systemic therapy) and in establish-
ing the likely prognosis. Determining the presence of metas-
tasis both at presentation and after initial treatment is a key
factor in optimal diagnosis and determining ongoing treat-
ment [1, 2]. Despite guidelines it is unclear if there is consis-
tency as to the most appropriate initial staging investigations,
and therefore the type and timing of staging investigations
vary greatly between units.
The likelihood of metastatic disease at the time of breast
cancer diagnosis is very low [1], so there is no clear evidence
to support universal baseline intensive staging, and in fact
several studies have suggested that staging in this manner is
of limited value [1–7]. The yield of staging investigations is
particularly low for patients with small tumours and negative
axillary nodes. However, many patients continue to undergo
extensive staging at the time of diagnosis [8–10]. Overstaging
can lead to unnecessary resource use (which could be better
used to appropriately stage other patients), unnecessary psy-
chological distress [11], and possible delays to treatment.
Evidence-based guidelines aid treatment decisions and
ensure quality and consistency in care [12]. Breast cancer is
common, and treatment pathways therefore carry consider-
able resource implications. Understanding clinical practice in
the staging of early breast cancer, and consideration of how
well this practice mirrors available clinical guidelines is,
therefore important. Several global guidelines have been pro-
duced in recent years to reduce the number of staging inves-
tigations carried out for women with early breast cancer [13–
17].
This study aims to gain insight into the preferences and
practice of surgeons and breast units in the United Kingdom
with regard to staging for distant disease in breast cancer
through a survey distributed to breast surgeons working
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within the United Kingdom. Respondents were identified
through their membership in the Association of Breast Sur-
gery (ABS), the main subspecialty professional organization
covering the treatment of breast cancer in the United King-
dom and Northern Ireland. It is outside the scope of this
paper to consider staging following a diagnosis of local recur-
rence, and so the remainder of this work focuses on staging in
the setting of primary breast cancer.
2. Methods
Anonline surveywas designed, containing questions pertain-
ing to surgeon/breast unit demographics, availability and use
of various staging investigations, and local policy on choice of
pre/postoperative staging investigations. Several patient sce-
narios were also presented to determine whether consensus
exists as to the choice of staging investigations in particular
situations. The survey can be viewed online at http://www
.surveymonkey.com/breastcancerstaging.
Respondents were identified from themembership direc-
tory of theABS as breast surgeonsworking in England,Wales,
Scotland and Northern Ireland.The survey was disseminated
to all members of ABS by e-mail via correspondence directly
from the association. Results were collated and analyzed
using Microsoft Excel 2008 for Mac and SPSS v 12.0.
3. Results
Four hundred and seventy-four members listed in the ABS
directory were e-mailed a link to the online survey (Septem-
ber, 2011). 123 recipients completed the survey (response rate
26%). From those responding a median of 3 surgeons work
in each breast unit (range 1–8). Respondents were widely
geographically spread within England, but underrepresented
in Scotland,Wales, andNorthern Ireland.Thenumber of new
cancer diagnoses seen by respondents’ units broadly spanned
the range of options given (Figure 1).The greatest proportion
of responding units see 201–300 new cancers per year.
Respondents were asked to indicate whether various
staging modalities are either available at their unit, available
at a regional hospital, or not available to them at all. The vast
majority of units offer blood tests (114, 99%), CXR (114, 99%),
CT (114, 99%), Magnetic resonance imaging (MRI) (110,
95.7%), and liver ultrasound (LUS) (115, 100%). Bone scintig-
raphy (BS) is only available at a regional hospital for 11 (10%)
respondents and not available at all for 1 (1%) respondent.
Positron emission tomography (PET/CT) is only available at a
regional hospital for 61 (57%) respondents andnot available at
all for 6 (6%) respondents.
Respondentswere asked to indicatewhich staging investi-
gations are routinely employed for all patients diagnosed with
early breast cancer (covering both staging for treatment plan-
ning, e.g., axillary ultrasound [AUS] andMRI, and staging for
metastatic disease).Themajority of respondents routinely use
common blood tests (full blood count 91 (74%) respondents;
routine biochemistry 90 (73%); liver function tests 86 (70%)).
Approximately half of respondents (63, 51%) routinely use
serum calcium/bone profile and 5 (4%) routinely use serum
1–100 101–200 201–300 301–400 401–500 >500
0
5
10
15
20
25
30
35
Number of new breast cancer cases
N
um
be
r o
f r
es
po
nd
en
ts
Figure 1: Number of New Breast Cancers seen by Respondents’
Units.
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Figure 2: Investigations routinely performed for all patients with
early breast cancer.
tumour markers. No respondents routinely employ MRI or
PET/CT scans; only 1 respondent (1%) usesCT scanning, 1 BS,
and 3 respondents (2%) use LUS routinely in early breast can-
cer to search for metastatic disease. CXR is used routinely by
approximately one third of respondents (44, 36%) and AUS
by two-thirds (82, 67%) (Figure 2).
Respondents were then asked to describe their units’
criteria for preoperative and postoperative staging for distant
metastases in asymptomatic patients by CT scan for each of
five themes: size, axillary nodal status, patient age, plan for
neoadjuvant/adjuvant chemotherapy, and histological type of
tumour. The overwhelming majority of respondents do not
use patient age or histological type of tumour in decision-
making for CT staging either pre- or postoperatively (96
(99%), 86 (91%) 89 (98%), and 79 (89%), resp.).
Two-thirds (64, 67%) of respondents always perform CT
staging prior to neoadjuvant chemotherapy whilst signifi-
cantly fewer (17, 19%) do prior to adjuvant chemotherapy
(𝑃 < 0.0001).
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Figure 3: Criteria for pre- and postoperative CT staging for metastatic disease.
Tumour size and axillary nodal histology resulted inmore
heterogeneous responses (Figure 3). Almost half (46, 46%) of
respondents would perform CT preoperatively for a T3/T4
tumour. There was no significant difference in decisions to
perform CT scanning based on T-stage pre- and postopera-
tively (𝑃 = 0.33).
The majority (85, 86%) of respondents stated that their
units use CT preoperatively in the event of clinical/radiolog-
ical evidence of nodal involvement. Units are much more
likely to utilise CT scanning postoperatively for patients with
multiple (>1) nodes than single nodal involvement (𝑃 =
0.0005) (Figure 3).
4. Clinical Scenarios
Respondents were given eight patient scenarios, each with a
supporting illustration (Figure 4) and asked to indicate which
staging investigations they would employ in each situation.
4.1. Scenario 1: Preoperative 43-Year-Old Female; Imaging
45mm M5 U5; Core Biopsy; Grade 2 Invasive Ductal Carci-
noma; Axillary Ultrasound Negative. 83 respondents (81%)
indicated that they would perform blood tests and almost
half (44, 43%) a CXR. 12 respondents would perform BS and
12 (12%) CT. 5 respondents (5%) would perform LUS, whilst
1 (1%) respondent chose PET/CT. 20 respondents (19%)
answered that they would not perform any staging investi-
gations.
4.2. Scenario 2: Preoperative 43-Year-Old Female; Imaging
45mm M5 U5; Core Biopsy Grade 2 Invasive Ductal Carci-
noma; Axillary Ultrasound and Needle Biopsy Proven Meta-
static Node. For this scenario, 13 respondents (13%) indicated
that they would not perform any staging investigations. 81
respondents (81%)would performblood tests, 42 (42%)CXR,
39 (39%) CT, 32 (32%) BS, and 4 (4%) LUS. Comparing Sce-
narios 1 and 2, significantlymore respondents chose to under-
take CT staging in a patient with confirmed axillary nodal
spread (𝑃 = 0.0003).
4.3. Scenario 3: Preoperative 36-Year-Old Female; Imaging
70mm Malignant Microcalcifications; Core Biopsy Interme-
diate/High Grade DCIS; Axillary Ultrasound Negative. 25
respondents (25%) indicated that they would not request any
staging investigations, while 75 (74%) would perform blood
tests, 33 (33%) CXR, 4 (4%) CT, 4 (4%) BS, and 2 (2%) LUS.
Comparing Scenarios 1 and 3, there was no significant dif-
ference in respondents’ preoperative staging preferences in a
patient with widespread DCIS compared with proven inva-
sive disease in the absence of abnormal axillary nodes.
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Figure 4: Illustrations for patient scenarios.
4.4. Scenario 4: Postoperative 69-Year-Old Female; Histology
28mm Grade 3 Invasive Lobular Carcinoma, 3/19 Involved
Lymph Nodes. In response to this scenario, 62 respondents
(63%)would request blood tests, 50 (51%) CT, 40 (41%) BS, 27
(28%) CXR, and 4 (4%) LUS.
4.5. Scenario 5: Postoperative 69-Year-Old Female; Histology
28mm Grade 3 Invasive Lobular Carcinoma, 17/19 Involved
Lymph Nodes. All respondents chose to undertake some
form of staging investigations. 99 respondents (98%) would
request a CT, 84 (83%) BS, 67 (66%) blood tests, 25 (25%)
CXR, and 6 (6%) LUS.No respondents chose PET/CT. Signif-
icantly more respondents would perform CT staging in this
scenario of a patient with significant axillary nodalmetastasis
(98.0%), compared with Scenario 4 (40.8%) in which the
patient had limited nodal disease (𝑃 < 0.0001).
4.6. Scenario 6: Postoperative 85-Year-Old Female; Histology;
20mm Grade 2 Invasive Ductal Carcinoma, Sentinel Node
Negative. Just over half of respondents (52, 52%) chose not
to undertake any staging for this patient. Of the remainder,
47 (47%) chose to perform blood tests, 31 (31%) CXR, and 1
(1.0%) LUS. No respondents would perform CT, PET/CT, or
BS.
4.7. Scenario 7: Postoperative 49-Year-Old Female; Histology
Multifocal High-Grade DCIS, Sentinel Node Negative. 60
respondents (59%) did not undertake any staging for this
patient. Of the remainder, 40 (40%) chose blood tests, 18
(18%) CXR, 1 (1%) LUS, 1 (1%) CT, and 1 (1%) BS. No respon-
dents chose to undertake PET/CT. Significantly fewer respon-
dents opted to undertake postoperative staging in this sce-
nario in which the patient has histological confirmation of in
situ disease only, compared with Scenario 4 where the preop-
erative diagnosis is of widespread high-grade DCIS (𝑃 =
0.0028).
4.8. Scenario 8: Postoperative 62-Year-Old Male; Imaging:
14mmMalignant Lesion; Core Biopsy Grade 3 Invasive Ductal
Carcinoma;AxillaryUltrasound andBiopsy Positive forMetas-
tasis. For this scenario, only 13 respondents (13%) chose not
to undertake any staging investigations. 83 respondents (81%)
chose blood tests, 40 (39%) CXR, 40 (39%) CT, 36 (35%) BS,
and 4 (4%) LUS.There was no statistical difference in respon-
dents’ staging preferences formales comparedwith females in
this scenario (Scenarios 4 and 6).
It is evident from all of the scenarios that respondents are
choosing to perform virtually no PET/CT scan at all and very
few liver ultrasounds but are undertaking a significant num-
ber of bone scans.
Respondents were asked whether their unit’s staging
preferences would be different if they were not subject to
any financial constraints. Only 14 (11%) answered “Yes,” with
several respondents commenting that CT staging should
be offered for all axillary node-positive patients. Another
respondent commented that PET/CT would be the main
initial staging tool in the absence of financial constraints.
Respondents were then given the opportunity to leave
comments regarding staging for breast cancer. The majority
of respondents commented either that they believed that rou-
tine staging for metastasis is of little value or that their unit
had recently changed its practice and was performing fewer
staging investigations. Comments also suggested that respon-
dents are more likely to perform staging investigations for
lobular cancers, neoadjuvant chemotherapy, preoperative
clinical/radiological evidence of nodal involvement, locally
invasive tumours, recurrent tumours, and inflammatory can-
cers.
5. Discussion
Staging for distant metastatic disease in early breast can-
cer remains inconsistent, as illustrated by the incongruous
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responses given by respondents to the patient scenarios in
our survey. The group responding to this survey practice in
units across theUnitedKingdomand almost half workwithin
units treating over three hundred new breast cancer cases per
year. These results are therefore unlikely to be explained by
geographical variance or caseload. Furthermore, the staging
preferences of our respondents are unlikely to be significantly
affected by access restrictions, as the vast majority of our
respondents work within units with good availability of all
staging investigations with the exception of PET/CT.
Common sites of metastatic disease in breast cancer
include bone, lung, and liver. Traditionally, staging investiga-
tions have therefore included isotope bone scan, chest radio-
graphy, and liver ultrasound. All of the staging investigations
commonly employed in breast cancer (including CXR, BS,
LUS as well as biochemical assays and tumour markers) have
been shown to have very low detection rates when used at the
time of diagnosis. Schneider et al. [7] found that the overall
rate of distant metastasis was only 3.9%, and several papers
have reported the detection rates of individual staging investi-
gations. For isotope bone scan this has been published as 0.5–
11% [5, 7, 18–23], for liver ultrasound 0.24–3.3% [5, 7, 20, 24],
and for chest radiography 0.2–1.2% [7, 18, 20, 25, 26].
Older guidelines, such as the National Comprehensive
Cancer Network [16] recommended a comprehensive base-
lineworkup; however, several studies have found that the rou-
tine undertaking of staging investigations is unnecessary, and
this is now reflected in current guidelines. A large study found
that of the 80% patients diagnosed with early breast cancer
undergoing baseline BS, skeletal metastasis was only detected
in approximately 6%, whilst baseline CXR and LUS had even
lower pick-up rates [27]. In a cohort of 781 patients evaluated
byMorris et al., 34% underwent a staging bone scan, but only
14.3% patients presented with metastatic disease at any site,
and the yield of bone scans was only 15.8% [28]. Importantly
in this study, themajority of patients found on staging isotope
bone scan to have skeletal metastases were symptomatic, and
there was high clinical suspicion in the vast majority of the
remainder. This amounted to an incidental bony metastasis
rate of only 1% [28]. Morris et al. also examined the use of
staging liver investigations in their cohort and found that
the yield of LUS was also very low (8.8%), and again the
rate of incidental hepatic metastases found at ultrasound was
less than 1% [28]. In contrast, they found that the negative
predictive value of normal liver function tests was 97.6%.This
suggests that patients should undergo liver biochemistry rou-
tinely, particularly as they present much lower cost [28], but
our survey would suggest that over 30% of respondents are
not using liver function tests routinely.
Notwithstanding this evidence, our results show that tra-
ditional investigationmodalities are still being used routinely
in some units, particularly chest radiography. Yet only two-
thirds of respondents responded to using preoperative axil-
lary ultrasound despite clear national recommendations [13].
Despite the wide availability of accurate imaging tech-
niques, many still consider clinical staging to be the most
useful, not least of which because it is the most cost-effective
[29, 30]. Samant and Ganguly [5] reported that most patients
(84%)with radiologicalmetastases at the time of presentation
had clinical signs or symptoms suggestive of metastatic dis-
ease, a finding which has been previously reported [31].
Moreover, the diagnostic accuracy of the imaging modal-
ities employed in breast cancer staging can be variable: bone
scanning has been described as producing 10–15% false neg-
ative and 10–30% false positive results [9, 18, 32, 33]. Routine
LUS detects many incidental benign findings with a false
positive rate reported as 33–52% [1, 34]. CXR too may have a
considerable false-positive rate, reported as 0–23% [34]. Fur-
thermore, staging investigations in patients with lower stage
breast cancer are proportionally more likely to give false-
positive results [1].
Evidence-based clinical practice guidelines have the ben-
efit of allowing clinicians to utilise the outcomes of litera-
ture efficiently after they have been systematically reviewed,
appraised, and summarised. Several guidelines have been
issued which contain recommendations for breast cancer
staging, including the Cancer Care Ontario (CCO) [15],
National Comprehensive Cancer Network (NCCN) [16], the
National Institute for Clinical Excellence (NICE) [13], and the
British Association of Surgical Oncology (BASO) [14].
Hogeveen et al. [12] reviewed guidelines published by the
American Society of Clinical Oncology (ASCO), CCO, and
NICE regarding breast cancer treatment using the Appraisal
of Guidelines for Research and Evaluation (AGREE) instru-
ment. They found the guidelines to be consistently good in
terms of scope, purpose, rigour of development, and clarity and
presentation. However, they suggested that certain guidelines
lacked strength in stakeholder involvement, applicability, and
editorial independence. In terms of staging investigations and
follow-up, the NICE guidelines consistently received the
highest scores, although the key recommendations are con-
sistent between organizations.
Han et al. [11] found that 55% of newly diagnosed early
stage breast cancer patients underwent unnecessary investi-
gations, which suggests that adherence to guidelines for the
postoperative staging of patients with breast cancer is poor.
This mirrors results from several other studies [27, 28, 35].
Improving adherence to national guidelines may well free up
resources to be used in reducing time to treatment and in the
staging of appropriate patients [11]. It has also been shown
that staging investigations increase psychological distress [27,
35], and omitting these where unnecessary will therefore
potentially lead to improved patient experience. It has been
reported that simply disseminating clinical guidelines is often
not effective in changing doctors’ behaviour and improving
patient outcomes [36]. McWhirter et al. [36] showed that
requests for staging investigations in early-stage breast cancer
reduced following a directed educational intervention.
National guidelines in the United Kingdom have been
described as somewhat nonspecific and open to interpreta-
tion [37]. They do, however, have in common an encourage-
ment to limit staging to only those with locally advanced dis-
ease. The staging of patients with T4 disease or any evidence
of malignant lymphadenopathy is very clear [37], however,
guidance for patients outside these categories but with
“locally advanced disease” is less explicit. NICE recommends
only that patients with T4 tumours (stage III+) should be
preoperatively staged but do not clearly advocate any one
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imaging modality over another [13]. They further emphasise
that patients “with early breast cancer should not undergo
staging for distant metastatic disease in the absence of symp-
toms” [13]. BASO clearly states that “a preoperative search for
occult metastases by bone scan and liver ultrasound does not
yield useful information in patients with operable primary
breast cancer” and that therefore “these investigations should
not normally be carried out unless the patient is symptomatic,
partaking of a clinical trial, or recommended for neoadjuvant
therapy” [14]. They suggest that no asymptomatic patients
should be routinely preoperatively staged, other than using
full blood count, routine biochemistry, and liver function
tests and perhaps using plain chest X-ray according to local
protocol [14]. Our results show that respondents are in fact
rationalising the use of routine staging, with the vast majority
of respondents only choosing to undertake blood tests and/or
chest X-ray routinely, and only a handful employing any other
modality in the preoperative setting (Figure 2). However,
when asked to describe their criteria for staging by CT scan,
over 20% respondents would stage a patient with clinically
less than T4 disease (Figure 3). Whilst preoperative axil-
lary nodal involvement is not explicitly described in either
national guideline as a reason to undertake staging, it is a
factor in over three-quarters of respondents’ staging practice.
However, it is also clear that practice is not systematic in terms
of the number of involved nodes (or indeed whether they are
clinically rather than radiologically apparent).
Examining the responses to clinical scenarios further
emphasises a lack of unified practice, particularly for patients
with stage II breast cancer. Scenario 1 described a patient with
T2 (stage IIA) disease and therefore according to national
guidelines ought not to undergo any radiological staging for
metastatic disease in the absence of symptoms. However, our
results showed that 12% would request a bone scan and 12%
CT scan. Similarly, the patients described in scenarios 2 and 4
haveT2 (stage IIB) disease, and yet in Scenario 2, 39% respon-
dents would undertake CT scan, 32% bone scan, and 4%
liver ultrasound, while in Scenario 4 over half of respondents
would request CT, over 40% a bone scan. Scenario 5 describes
a patient with stage IIIC disease, and appropriately most
respondents chose to undertake some form of radiological
staging. Similarly, in Scenario 6 describing a patient with T1
(stage IA) disease, the vast majority of respondents chose not
to undertake any radiological staging. These results indicate
that at the extremes of disease, practice is consistent but that
for those patients within the broad category of stage II disease
it is much less so.
So which patients should undergo staging for metastasis?
There is clear evidence that certain patient and tumour factors
are associated with a higher likelihood of regional/distant
metastatic disease in breast cancer, in particular disease stage
[1, 2] (the American Joint Committee on Cancer (AJCC)
staging classification for breast cancer can be accessed online
[38]). Ravaioli et al. reported a prevalence of metastasis of
1.46% in low-risk patients (pT1–T3 and ≤3 positive nodes)
compared with 10.68% in high-risk patients (pT4 or >3 posi-
tive nodes or pN2) as revealed by bone scan, liver ultrasound,
and chest X-ray in combination [2].They divided their cohort
of 406 patients into three risk groups based on tumour and
nodal stage. In their highest-risk group (T4, N1/2) the detec-
tion rate for distant metastases at staging was 15.53% leading
them to recommend full staging for this group including
chest X-ray, liver ultrasound, and bone scan.They went on to
recommend laboratory tests and physical examination alone
as adequate staging for the lowest (T1, N0-1) and moderate
(T2, N0/1 or T3, N0/1) risks groups. In the cohort of 488
reviewed by Schneider et al. [7], none of the 19 patients found
to have distantmetastases at the time of diagnosis had tumour
smaller than 1 cm, but over 18% of patients with pT4 tumours
were found to have distant metastases. Bozcuk et al. [39]
investigatedmultiple patient and pathological factors in order
to identify independent predictors of distant metastasis at the
time of presentation. Tumour diameter (>2 cm), lymph node
involvement (1 or more) and tumour grade were statistically
significant predictors of metastasis. The only others were p53
and C-erB-2 positivity, whilst several other factors including
age, pathological type, and ER/PR positivity were not predic-
tive. Based on an extensive review of the efficacy of screening
investigations at demonstrating metastases in asymptomatic
postoperative patients, Myers et al. [1] (for the Breast Cancer
Disease Site Group of the Cancer Care Ontario Practice
Guidelines Initiative) have developed a series of clear recom-
mendations regarding screening. They concluded that bone
scanning, liver ultrasound, and chest X-ray are not indicated
either routinely, for in-situ/Stage I disease, or for women in
whom treatment options are limited or no further treatment
is possible due to age or comorbidity. They recommend bone
scanning for Stage II disease and bone scanning, liver ultra-
sound, and chest X-ray for Stage III tumours [1].The patients
in scenarios 4 and 6 of our survey have histologically stage
II disease, yet only 27.6% and 0% respondents, respectively,
chose to undertake bone scanning. Similarly, the patient in
Scenario 5 has stage III disease, where 83.2% respondents
chose to undertake a bone scan and 24.8% a chest X-ray. Only
5.9% respondents chose to undertake liver ultrasound, how-
ever, this is mitigated by virtually all respondents choosing
instead to request CT scanning. Barrett et al. reviewed over
2600 asymptomatic patients with newly diagnosed breast
unit and confirmed that the incidence of occult metastasis
increases with tumour stage (present in 6, 13.9, and 57% of
patients with stage II (where ≥4 involved lymph nodes), III
and IV disease resp.). They therefore concluded that only
patients with stage III and IV disease at diagnosis require bas-
eline staging [37]. They further suggested CT as the staging
investigation of choice based on high specificity and conve-
nience [37]. Routine staging CT, however, has been reported
as being of little value even in poor prognostic group patients
(as defined by the Nottingham Prognostic Index), with a low
pickup rate and considerable rate of false positives [40].
Unfortunately, these guidelines all have the disadvantage
of requiring knowledge of tumour size and definitive axil-
lary status, which therefore precludes preoperative staging.
Clinical judgement must dictate these decisions, taking into
account a thorough history and clinical examination to
include symptoms of metastatic disease such as bone pain.
Rapidly enlarging or inflammatory tumours should prompt
consideration of preoperative staging. Preoperative AUS
(an important component of the NICE guideline) yields
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important information not only for operative planning but
also regarding stage and prognosis which can inform fur-
ther staging decisions, and therefore its routine use should
therefore be encouraged. It may also be possible to rationalize
the number of staging modalities as radiological techniques
are refined. Bristow et al. investigated the concordance of
CT scanning with bone scintigraphy in diagnosing bony
metastasis in breast cancer. They found that 98% of patients
with BS evidence of metastasis were diagnosed on CT of the
thorax, abdomen, and pelvis and therefore suggested that
routine BS is not required if CT is being performed [41].
So it is apparent that although guidelines do exist which
address the question of staging for distant disease, responses
from the questionnaire suggest that practice appears to
remain inconsistent amongst UKbreast surgeons.This is seen
both in variation in suggested practice compared with avail-
able guidelines as well as variability in practice between
surgeons in the UK. Compliance with national recommen-
dations is reliant upon a combination of resource availability
and faith in both the legitimacy of the guidelines as well as
the integrity of the evidence on which they are based.
6. Conclusion
Clinical and radiological staging in breast cancer is an impor-
tant component of patient management. Despite national
guidelines, there remains wide variation with regards to stag-
ing investigations in early breast cancer. This survey suggests
that UK breast surgeons favour intensive staging of certain
higher-risk subgroups.
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